Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 211

1.

Clinical and economic impact of etanercept in real-life: a prospective, non-interventional study of etanercept in the treatment of patients with moderate to severe plaque psoriasis in private dermatologist settings (ESTHER).

Larsen CG, Andersen PH, Lorentzen H, Zachariae C, Huldt-Nystrøm T, Dotterud LK, Lindkvist RM, Qvitzau S.

Eur J Dermatol. 2013 Nov-Dec;23(6):774-81. doi: 10.1684/ejd.2013.2173.

PMID:
24334009
2.

Economic evaluation of etanercept in the management of chronic plaque psoriasis.

Lloyd A, Reeves P, Conway P, Reynolds A, Baxter G.

Br J Dermatol. 2009 Feb;160(2):380-6. doi: 10.1111/j.1365-2133.2008.08863.x. Epub 2008 Sep 19.

PMID:
18808413
3.

Etanercept and infliximab for the treatment of psoriatic arthritis: a systematic review and economic evaluation.

Woolacott N, Bravo Vergel Y, Hawkins N, Kainth A, Khadjesari Z, Misso K, Light K, Asseburg C, Palmer S, Claxton K, Bruce I, Sculpher M, Riemsma R.

Health Technol Assess. 2006 Sep;10(31):iii-iv, xiii-xvi, 1-239. Review.

4.

Cost-effectiveness of psoriasis therapy with etanercept in Germany.

Heinen-Kammerer T, Daniel D, Stratmann L, Rychlik R, Boehncke WH.

J Dtsch Dermatol Ges. 2007 Sep;5(9):762-8. English, German.

PMID:
17760896
5.

Cost effectiveness of moderate to severe psoriasis therapy with etanercept and ustekinumab in the United States.

Villacorta R, Hay JW, Messali A.

Pharmacoeconomics. 2013 Sep;31(9):823-39. doi: 10.1007/s40273-013-0078-x.

PMID:
23975739
6.

Employment is maintained and sick days decreased in psoriasis/psoriatic arthritis patients with etanercept treatment.

Boggs RL, Kárpáti S, Li W, Williams T, Pedersen R, Mallbris L, Gniadecki R.

BMC Dermatol. 2014 Aug 5;14:14. doi: 10.1186/1471-5945-14-14.

8.

Utilization pattern of etanercept and its cost implications in moderate to severe psoriasis in a managed care population.

Wu EQ, Feldman SR, Chen L, Kaltenboeck A, Yu AP, Gupta SR, Laitinen D, Willian MK.

Curr Med Res Opin. 2008 Dec;24(12):3493-501. doi: 10.1185/03007990802551057 .

PMID:
19032131
9.

Sustained improvement in joint pain and nail symptoms with etanercept therapy in patients with moderate-to-severe psoriasis.

Luger TA, Barker J, Lambert J, Yang S, Robertson D, Foehl J, Molta CT, Boggs R.

J Eur Acad Dermatol Venereol. 2009 Aug;23(8):896-904. doi: 10.1111/j.1468-3083.2009.03211.x. Epub 2009 May 3.

PMID:
19453794
10.

Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.

Mazzotta A, Esposito M, Costanzo A, Chimenti S.

Am J Clin Dermatol. 2009;10(5):319-24. doi: 10.2165/11310770-000000000-00000.

PMID:
19658444
11.

Work productivity and healthcare resource utilization outcomes for patients on etanercept for moderate-to-severe plaque psoriasis: results from a 1-year, multicentre, open-label, single-arm study in a clinical setting.

Vender R, Lynde C, Ho V, Chau D, Poulin-Costello M.

Appl Health Econ Health Policy. 2012 Sep 1;10(5):343-53. doi: 10.2165/11633980-000000000-00000.

PMID:
22877226
12.

Cost effectiveness of biologic therapies for plaque psoriasis.

Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR.

Am J Clin Dermatol. 2013 Aug;14(4):315-26. doi: 10.1007/s40257-013-0030-z. Review.

PMID:
23696234
13.

Long-term safety and efficacy of 50 mg of etanercept twice weekly in patients with psoriasis.

Tyring S, Gordon KB, Poulin Y, Langley RG, Gottlieb AB, Dunn M, Jahreis A.

Arch Dermatol. 2007 Jun;143(6):719-26.

PMID:
17576937
14.

A randomized study to evaluate the efficacy and safety of adding topical therapy to etanercept in patients with moderate to severe plaque psoriasis.

Lebwohl MG, Kircik L, Callis Duffin K, Pariser D, Hooper M, Wenkert D, Thompson EH, Yang J, Kricorian G, Koo J.

J Am Acad Dermatol. 2013 Sep;69(3):385-92. doi: 10.1016/j.jaad.2013.03.031. Epub 2013 May 1.

PMID:
23643256
15.

Etanercept improves quality of life outcomes and treatment satisfaction in patients with moderate to severe plaque psoriasis in clinical practice.

Vender R, Lynde C, Gilbert M, Ho V, Sapra S, Poulin-Costello M.

J Cutan Med Surg. 2012 Nov-Dec;16(6):407-16.

PMID:
23149196
16.

Effect of infliximab on health-related quality of life and disease activity by body region in patients with moderate-to-severe psoriasis and inadequate response to etanercept: results from the PSUNRISE trial.

Kalb RE, Blauvelt A, Sofen HL, Chevrier M, Amato D, Calabro S, Wang J, Schenkel B, Gottlieb AB.

J Drugs Dermatol. 2013 Aug;12(8):874-80.

PMID:
23986160
17.

A retrospective study to investigate racial and ethnic variations in the treatment of psoriasis with etanercept.

Shah SK, Arthur A, Yang YC, Stevens S, Alexis AF.

J Drugs Dermatol. 2011 Aug;10(8):866-72.

PMID:
21818507
18.
20.

Etanercept treatment for children and adolescents with plaque psoriasis.

Paller AS, Siegfried EC, Langley RG, Gottlieb AB, Pariser D, Landells I, Hebert AA, Eichenfield LF, Patel V, Creamer K, Jahreis A; Etanercept Pediatric Psoriasis Study Group.

N Engl J Med. 2008 Jan 17;358(3):241-51. doi: 10.1056/NEJMoa066886.

Supplemental Content

Support Center